[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100075322":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":26,"locations":39,"responsibleParty":47,"collaborators":26,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":26,"enrollmentInfo":59,"targetDuration":26,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":74,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Abbott","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"A","EXPERIMENTAL","2 drug arm",[13,14],"Drug: Tenofovir DF","Drug: lopinavir\u002Fritonavir with 2 Nucleoside RTIs",{"label":16,"type":17,"description":18,"interventionNames":19},"B","ACTIVE_COMPARATOR","3 drug arm, SOC",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tenofovir DF","TDF 300mg QD for 72 wks",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"lopinavir\u002Fritonavir with 2 Nucleoside RTIs","LPV\u002FrSGC 400\u002F100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks",[9,16],[32,33,34],"ABT-378","Kaletra","lopinavir\u002Fritonavir",[36],{"name":37,"affiliation":5,"role":38},"Umberto di Luzio Paparatti, MD","STUDY_DIRECTOR",[40],{"facility":41,"status":26,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":26,"geoPoint":26,"contacts":26},"Global Medical Information-Abbott","Abbott Park","Illinois","60064","United States","US",{"type":26,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":48,"oldOrganization":5},"Dr. Umberto di Luzio Paparatti, Medical Director Abbott Italy","100075322","phase-3-efficacy-of-simplified-two-drug-kaletra-regimen-vs-kaletra-triple-drug-standard-of-care-regimen-in-treatment-nave-hiv-infected-patients-100075322",false,"NCT00234910","Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients","A Phase III, Open Label, Randomized, Comparative Study of the Antiviral Efficacy of ARV Therapy With Lopinavir\u002FRitonavir (LPV\u002Fr-Kaletra) in Combination With Tenofovir (TDF) Versus Standard of Care (Kaletra in Combination With 2 Nucleoside RTIs) in naïve-HIV-1 Positive Patients","KALEAD","Inclusion Criteria:\n\n* HIV positive\n* \\>18 years of age\n* HIV RNA\\> 400 copies\u002FmL\n* Any CD 4 cell count\n* Antiretroviral naïve\n* No acute illness\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":60,"type":61},152,"ACTUAL","INTERVENTIONAL",[64],"PHASE3","The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm.",[67],"HIV Infection",[69,70,33,71,72,73],"Lopinavir","Ritonavir","Tenofovir","HIV infection","Treatment Naive","COMPLETED","2008-07-09",{"date":77,"type":78},"2008-07-10","ESTIMATED",{"date":80,"type":26},"2005-01",{"date":82,"type":61},"2008-06",{"name":5,"class":6},1]